Pyrazinamide kills Mycobacterium tuberculosis via pH-driven weak-acid permeation and cytosolic acidification

Tuberculosis is an ancient enemy that still claims more lives today than any other infectious disease. For decades, doctors have relied on a specific cocktail of four drugs to treat it, a regimen that must be taken daily for six months. One of these drugs, pyrazinamide, is unique because it can kill the bacteria even when they are dormant and hiding, a state where most other antibiotics fail. However, for over seventy years, scientists have been unable to agree on exactly how this drug works. While the mechanisms of the other three drugs are well understood, the way pyrazinamide attacks the tuberculosis bacterium has remained a mystery, with two competing theories fighting for acceptance. One theory suggests the drug targets a specific enzyme inside the bacteria to starve it of essential nutrients. The other, older theory proposes that the drug acts like a chemical sponge, soaking up protons to acidify the bacteria's internal environment, but only when the outside world is already acidic.

A new study by researchers from France, Russia, Argentina, and the United States has finally settled this long-standing debate. By testing the drug under a wide variety of conditions, the team demonstrated that the drug does not rely on the specific enzyme theory. Instead, they confirmed that pyrazinamide works by entering the bacteria and dumping acid inside, a process that only happens when the environment outside is already acidic. This finding explains why the drug is so effective inside the human body, where the bacteria often hide in acidic pockets, but why it sometimes appears to fail in standard laboratory tests. The researchers also showed that the drug's ability to kill the bacteria is not a complex, multi-step process involving specific targets, but rather a direct physical effect of the drug changing the bacteria's internal chemistry.

The story of this drug begins with its discovery in the 1950s. Scientists found that a molecule called pyrazinamide could cure tuberculosis in mice, but when they tried to grow the bacteria in a standard liquid broth in a petri dish, the drug seemed to do nothing. This strange behavior led to the realization that the drug is a prodrug, meaning it is inactive until the bacteria itself changes it. Inside the bacteria, an enzyme converts pyrazinamide into a new form called pyrazinoic acid. For decades, the scientific community has been divided on what this new form does next. One group of researchers believed it binds to a specific protein called PanD, which is essential for making a molecule called coenzyme A, a vital fuel for the bacteria. If this were true, the drug would be acting like a key jamming a specific lock. Another group argued that the drug acts more like a weak acid, slipping through the bacterial wall and releasing hydrogen ions inside to lower the internal pH, effectively drowning the bacteria in its own acid.

To resolve this conflict, the researchers set up a series of experiments designed to test both ideas side by side. They started by growing the bacteria in different environments, some with a neutral pH and others with a slightly acidic pH, mimicking the conditions found in human tissues. They found that the drug was completely ineffective in neutral conditions but became highly potent as the environment became more acidic. This confirmed that the acidity of the surroundings is the switch that turns the drug on. However, this alone did not prove which of the two theories was correct, as both could theoretically be influenced by pH.

The team then turned their attention to the enzyme theory. They used a special strain of bacteria that had been genetically modified to lack the PanD enzyme entirely. If the drug worked by jamming this specific enzyme, then a bacteria without the enzyme should be immune to the drug, or at least much harder to kill. The researchers also added extra amounts of the nutrients that the enzyme usually produces to see if this would protect the bacteria. In standard laboratory media, adding these nutrients did seem to protect the bacteria, which had led many to believe the enzyme theory was correct. However, the researchers suspected that the standard laboratory food might be misleading. They switched to a custom-made growth medium that used a different type of fat as the primary food source, which is more similar to what the bacteria eats inside a human lung. In this more realistic environment, the protective effect of the added nutrients vanished. The bacteria without the enzyme were killed just as easily as the normal ones, proving that the drug does not need the enzyme to work.

To see exactly what was happening inside the bacteria, the researchers used a clever tool: a strain of tuberculosis bacteria that glows with a specific color depending on its internal acidity. They watched these glowing bacteria under a microscope while adding the drug. In neutral conditions, the bacteria remained healthy and their internal glow stayed steady. But as soon as the environment became acidic and the drug was added, the bacteria's internal glow shifted, indicating that their insides had become much more acidic. This acidification happened in both growing bacteria and dormant ones, and it occurred regardless of whether the bacteria had the enzyme or not. The drug was simply flooding the cell with protons.

The researchers then took this investigation a step further to understand the physical mechanism. They wanted to know if the drug was acting like a proton pump, actively shuttling acid across the membrane, or if it was simply diffusing through like a weak acid. They created artificial bubbles made of pure fat, called liposomes, which contained no proteins or enzymes, just a membrane. When they added the drug to these bubbles in an acidic solution, the inside of the bubbles became acidic. This proved that the drug does not need any biological machinery to work; it is a simple chemical process where the drug enters the cell in its neutral form and then releases a proton once inside. The researchers also tested whether the drug could act as a protonophore, a molecule that shuttles protons back and forth across a membrane to collapse energy gradients. Their tests showed that the drug does not do this; it acts strictly as a weak acid that enters and stays, acidifying the interior until the bacteria can no longer survive.

The study also addressed why the drug seemed to work differently in various lab settings. The researchers found that the type of food the bacteria eats changes how the drug behaves. In standard lab media containing glycerol, the drug appeared less effective, and the presence of certain nutrients seemed to block its action. But when they used a medium with oleic acid, a fat that is more common in the human body, the drug became highly effective, and the blocking effect of the nutrients disappeared. This explains why the drug has been so hard to study in the past; the standard lab conditions were creating an artificial environment that masked the drug's true power.

Ultimately, this work provides a clear and unified picture of how pyrazinamide kills tuberculosis. It is not a complex puzzle involving a specific enzyme target. Instead, it is a direct, physical attack on the bacteria's internal balance. The drug waits for the environment to be acidic, slips into the bacteria, and releases protons that the cell cannot neutralize. This acidification is what kills the bacteria, whether they are actively growing or hiding in a dormant state. The findings suggest that the enzyme theory, while it explains some minor resistance seen in the lab, is not the main way the drug works in a real infection. By confirming that the drug relies on a simple weak-acid mechanism, the researchers have provided a clearer path for understanding why the drug works so well in patients and how it might be improved in the future. The mystery of pyrazinamide is finally solved, revealing a mechanism that is as straightforward as it is effective.